10,385 Shares in Haemonetics Co. (NYSE:HAE) Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Haemonetics Co. (NYSE:HAE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,385 shares of the medical instruments supplier’s stock, valued at approximately $888,000.

A number of other hedge funds have also recently modified their holdings of the business. Norges Bank purchased a new position in Haemonetics in the 4th quarter worth about $28,591,000. Westfield Capital Management Co. LP increased its holdings in Haemonetics by 37.0% during the third quarter. Westfield Capital Management Co. LP now owns 559,963 shares of the medical instruments supplier’s stock valued at $50,161,000 after buying an additional 151,144 shares during the last quarter. Victory Capital Management Inc. raised its position in Haemonetics by 50.0% in the third quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock worth $32,007,000 after acquiring an additional 119,072 shares during the period. Kingdon Capital Management L.L.C. bought a new position in Haemonetics in the third quarter worth approximately $9,952,000. Finally, California Public Employees Retirement System grew its position in shares of Haemonetics by 36.9% during the 4th quarter. California Public Employees Retirement System now owns 229,717 shares of the medical instruments supplier’s stock valued at $19,643,000 after acquiring an additional 61,935 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 2.2 %

Shares of HAE opened at $93.20 on Wednesday. The firm has a market cap of $4.73 billion, a P/E ratio of 40.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.34. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The company has a 50 day simple moving average of $86.98 and a two-hundred day simple moving average of $83.38.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. During the same period in the previous year, the firm posted $0.77 EPS. Haemonetics’s revenue for the quarter was up 12.7% compared to the same quarter last year. On average, equities analysts expect that Haemonetics Co. will post 4.6 earnings per share for the current fiscal year.

Insider Activity at Haemonetics

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the sale, the executive vice president now owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $95.00, for a total value of $218,975.00. Following the completion of the transaction, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at $1,168,025. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Stewart W. Strong sold 733 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the sale, the insider now directly owns 15,608 shares in the company, valued at approximately $1,498,992.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,533 shares of company stock valued at $526,404. Insiders own 1.79% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the topic of several analyst reports. JMP Securities lifted their target price on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a research note on Friday, May 10th. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Barrington Research raised their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Finally, StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $108.67.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.